Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.51 |
| ▸ | CDC25B | P30305 | 8/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.49 |
| ▸ | TACR2 | P21452 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840884 | 1.00 | TP53 (0.55) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL16967451 | 1.00 | TP53 (0.55) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL15514084 | 1.00 | TP53 (0.55) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL7582210 | 0.97 | TP53 (0.55) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL11173059 | 0.96 | TP53 (0.52) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL13491599 | 0.96 | POLB (0.52) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL7583524 | 0.96 | POLB (0.52) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL16628842 | 0.95 | L3MBTL1 (0.58) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL16628841 | 0.95 | L3MBTL1 (0.58) | TP53MDM2POLBMDM4HSP90AA1 | |
| SCHEMBL6760496 | 0.94 | POLB (0.63) | TP53MDM2POLBMDM4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852414-B9 | MENINGOCOCCUS SEROGROUP X CONJUGATE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-12-09 | — | — | EP | disclosed |
| EP-2852414-B1 | MENINGOCOCCUS SEROGROUP X CONJUGATE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-07-08 | — | — | EP | disclosed |
| US-10668143-B2 | Meningococcus serogroup X conjugate | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-06-02 | — | — | US | disclosed |
| US-10124051-B2 | Meningococcus serogroup X conjugate | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-13 | — | — | US | disclosed |
| US-20180180626-A1 | A METHOD FOR DEVELOPMENT OF RECOMBINANT PROTEINS WITH FINGERPRINT LIKE SIMILARITY TO THE REFERENCE PRODUCT | STC BIOLOGICS INC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9868973-B2 | Method for optimizing post-translational modifications on recombinant proteins | STC BIOLOGICS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160340706-A1 | Method for Optimizing Post-Translational Modifications on Recombinant Proteins | STC BIOLOGICS, INC. | 2016-11-24 | — | — | US | disclosed |
| EP-3094639-A1 | METHOD FOR OPTIMIZING POST-TRANSLATIONAL MODIFICATIONS ON RECOMBINANT PROTEINS | Leszcyniecka, Magdalena (US) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015106276-A1 | METHOD FOR OPTIMIZING POST-TRANSLATIONAL MODIFICATIONS ON RECOMBINANT PROTEINS | LESZCYNIECKA MAGDALENA (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150104479-A1 | MENINGOCOCCUS SEROGROUP X CONJUGATE | NOVARTIS AG (CH) | 2015-04-16 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| US-4391800-A | Immunologically active peptidyl disaccharides and methods of preparation | MERCK & CO., INC. (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0018901-A1 | Immunologically active peptidyl disaccharides, methods of preparation and vaccine | MERCK & CO. INC. (US) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668143-B2 | Meningococcus serogroup X conjugate | O60361, MLEC, PDHX | TP53 3143/4885MDM2 2333/4885POLB 2095/4885 |
| US-20150104479-A1 | MENINGOCOCCUS SEROGROUP X CONJUGATE | O60361, MLEC, PDHX | TP53 3143/4885MDM2 2333/4885POLB 2095/4885 |
| US-10124051-B2 | Meningococcus serogroup X conjugate | O60361, PDHX, MLEC | TP53 3108/4885MDM2 2183/4885POLB 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.